Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DECODE GENETICS-*DCGN -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (304)	11/12/2008 8:27:14 AM
From: pgo-neil	Read Replies (2) \| Respond to of 313

Morningstar evaluates DCGN cash position as a "Zero dollar fair value" stock. Their liquid cash is about $11M, which matches their quarterly operating costs. They do have another $24M in, "Restricted, illiquid or noncurrent" investments. This would be another 2 quarters of operations if it could be liquidated. Sad since they will get no help from Iceland or its banks at this point. Who would be able to best use their unique datasets, IP for drug targets, and genetics test business? biz.yahoo.com deCODE Genetics (NasdaqGM:DCGN - News)From the Analyst Report: "DeCODE Genetics engages in some provocative research projects.... However, the company has yet to gain approval from the Food and Drug Administration for any of its products, and it is currently facing a severe liquidity crisis. It appears more likely to us that deCODE might no longer be a viable entity." graham --